Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The potassium inward rectifier channel subfamily J member 2 (Kir2.2, encoded by KCNJ2) is a tetrameric ion channel that allows K(+) ions to move more readily into cells than out, playing a critical role in maintaining the resting membrane potential of many cell types, especially cardiac and skeletal muscle cells[2][3][4][6]. Kir2.2 channels stabilize the membrane potential and are important for terminal repolarization during the cardiac action potential[4]. Channel opening is strongly dependent on binding of phosphatidylinositol 4,5-bisphosphate (PIP_2) at the interface between its transmembrane and cytoplasmic domains, which induces conformational changes to permit K(+) conduction[3][4][6]. Dysfunction or mutation of Kir2.2 (KCNJ2) is associated with inherited arrhythmia syndromes such as Andersen-Tawil syndrome and is also implicated in skeletal and smooth muscle excitability disorders[4]. Several drugs—including some antiarrhythmics—can interact with inward rectifier potassium channels and alter their function, which can pose risks of arrhythmia or be of therapeutic benefit in controlling abnormal heart rhythms[4]. The Kir2.2 channel is crucial for membrane stability, excitability, and the regulation of action potentials in excitable tissues[2][4].
Channel blockade (by antiarrhythmics, pharmacological inhibitors), Modulation of channel activity (via phospholipids such as PIP_2)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium inward rectifier channel subfamily J member 2 (Kir2.2).